Journal of Ayurveda and Integrated Medical Sciences

2025 Volume 10 Number 1 JANUARY
Publisherwww.maharshicharaka.in

A Standard Controlled Clinical Evaluation of Swedana and Agnikarma in Cervical Spondylosis (Manyastambha)

Singh H1*, KK Sharma2, Shukla GD3, Kumar D4
DOI:10.21760/jaims.10.1.5

1* Harpreet Singh, Post Graduate Scholar, Dept of Panchakarma, Uttrakhand Ayurveda University Rishikul Campus, Haridwar, Uttarakhand, India.

2 KK Sharma, Professor and HOD, Dept of Panchakarma, Uttrakhand Ayurveda University Rishikul Campus, Haridwar, Uttarakhand, India.

3 Gyanendra Datta Shukla, Associate Professor, Dept of Panchakarma, Uttarakhand Ayurved University Gurukul Campus, Haridwar, Uttarakhand, India.

4 Deepak Kumar, MBBS MS, FNB Orthopedic Spinal Surgeon, RKMS Hospital, Haridwar, Uttarakhand, India.

As exertion and stress is increasing day-by-day, diseases also increased in our daily routine. Prolonged sitting work, desktop work and continuous household work led to it. Degeneration of cervical spine components, such as facet joints and intervertebral discs, is known as cervical spondylosis. This degenerative process frequently causes stiffness, pain, and possible nerve compression in the neck, which can result in radicular symptoms such as upper extremity pain, numbness, or weakness. In Manyasthamba there is Vata Avarana by Kapha which later turns out to Kevala Vata Vyadhi. So, the present study aims at integrating Ayurvedic treatments with conventional approaches for cervical spondylosis addresses the condition holistically and treating not just the symptoms but also the root causes. The study entitled “A standard controlled clinical evaluation of Swedana and Agnikarma in cervical spondylosis (Manyastambha)” was conducted in 60 patients. They were selected on the basis of standard inclusion and exclusion criteria and randomly allocated to two different groups; Group - A (Ruksha Baluka Swedana, Punnagadi Patra Potali Swedana, Agnikarma) and Group - B (Controlled drug i.e., Pregabalin, Methyl cobalamin, Etoricoxib, Thiocolchicoside). Total duration of the treatment was of 16 days along with a follow-up period of 30 days. Both the intervention was effective, but in overall improvement of the patients “Group A” had shown better result along with long lasting effect in comparison with “Group B”.

Keywords: Cervical spondylosis, Manyasthamba, Swedana, Agnikarma, Ruksha Baluka Swedana, Punnagadi Patra Potali Swedana

Corresponding Author How to Cite this Article To Browse
Harpreet Singh, Post Graduate Scholar, Dept of Panchakarma, Uttrakhand Ayurveda University Rishikul Campus, Haridwar, Uttarakhand, India.
Email:
Singh H, KK Sharma, Shukla GD, Kumar D, A Standard Controlled Clinical Evaluation of Swedana and Agnikarma in Cervical Spondylosis (Manyastambha). J Ayu Int Med Sci. 2025;10(1):28-39.
Available From
https://jaims.in/jaims/article/view/3959

Manuscript Received Review Round 1 Review Round 2 Review Round 3 Accepted
2024-12-16 2024-12-23 2024-12-30 2025-01-10 2025-01-20
Conflict of Interest Funding Ethical Approval Plagiarism X-checker Note
None Nil Yes 13.36

© 2025by Singh H, KK Sharma, Shukla GD, Kumar Dand Published by Maharshi Charaka Ayurveda Organization. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/ unported [CC BY 4.0].

Download PDFBack To ArticleIntroductionAims and ObjectivesMaterials and MethodsObservations and ResultsDiscussionConclusionReferences

Introduction

Cervical Spondylosis is a degenerative disorder involving intervertebral discs, cervical spines and joints of the cervical region.[1]

It commonly occurs at the lowest three cervical intervertebral joints (C5-C6-C7). There is degeneration of the intervertebral disc with its protrusion and bony overgrowth of adjacent vertebrae, causing narrowing of the cervical canal and intervertebral foramina with resultant compression of nerve roots, cords, or both.

Symptoms of cervical spondylosis manifest as neck pain and neck stiffness and can be accompanied by radicular symptoms when there is compression of neural structures.

Based on sign and symptoms cervical spondylosis can be corelated with Manyastambha. Manyastambha is explained one of the Vataja Nanatmaja Vikara.[2]

According to Sushruta Samhita, the Vata Dosha and Kapha Dosha get aggravated and take Ashraya at Manya Pradesh, affecting the Manya Siras (nerves of neck) causing Ruja (pain) and Stambha (stiffness or difficulty in mobility) of the neck.[3]

In the initial stage of Manyasthambha there is Vata Avarana by Kapha which later, turns out to be a Kevala Vata (disease of Vata alone). So, in order to relieve the obstructing Kapha Dosha, Acharya Charka mentioned about Baluka Swedana.[4]

Patra Pinda Sweda is an effective treatment in painful conditions caused mainly by Vata Dosha, usually in degenerative diseases. According to Acharya Sushruta there is indication of Agni Karma in Snayu, Sandhi and Asthi Gata Vata. Agnikarma aims for the achievement of Apunarbhava Chikitsa. So, for the present study following line of treatment is chosen.

Aims and Objectives

1. To assess the efficacy of Ruksha Baluka Swedana, Punnagadi Patra Potali Swedana and Agni Karma in cervical spondylosis (Manyastambha).
2. To compare the efficacy of Ruksha Baluka Swedana, Punnagadi Patra Potali Swedana and Agni Karma with standard controlled group in cervical Spondylosis (Manyastambha).

Materials and Methods

For present clinical study, patients were completely screened on the basis of classical signs and symptoms of cervical spondylosis (Manyastambha) from the OPD and IPD of Panchakarma Department of Rishikul Campus Hospital, UAU, and RKMS Hospital, Haridwar.

Inclusion Criteria


  • Subject between the ages 20 to 60.
  • The subjects with classical signs and symptoms of Cervical Spondylosis and Manyastambha
  • Subjects fit and willing for Ruksha Baluka Swedana, Punnagadi Patra Potali Swedana, Agnikarma and Standard controlled drug.

Exclusion Criteria


  • Pregnancy and lactating mother
  • Subjects with uncontrolled HTN, diabetes and other systemic disorders that interfere in the line of treatment.
  • Subjects with Congenital deformity, Traumatic injuries, cervical stenosis and Myelopathy, Ankylosing spondylitis, Infections of bone and Gross bony deformity.
  • Any other known neurological disease.

Grouping

Group A: In 30 Patient, Ruksha Baluka Swedana was given for 5 days followed by Punnagadi Patra Pottali Swedana for 10 days and one sitting of Agnikarma was done on 16th day.

Group B:In 30 patient these drugs were given orally for 16 days.


  • Pregabalin 75mg - OD (HS)
  • Methyl cobalamin 1500mcg –OD
  • Etoricoxib 60mg-BD
  • Thiocolchicoside 4mg BD.

Criteria For Assessment

1. Pain (VAS scale)
jaims_3959_01.JPG


2.  StiffnessScore
No muscle stiffness0
Stiffness at one side but not causing any problem in activities1
Stiffness noticed spontaneously requiring analgesic therapy2
Severe or incapacitating discomfort3
3.  Pain on neck movementScore
No pain on neck movement0
Mild (<25%) and intermittent pain on neck movement to any side, with return to normal1
Moderate pain (25-60%) on neck movement to any side, requiring analgesic therapy2
Marked pain (51-71%) on neck movement to any side, requiring analgesic therapy3
Severe (>75%) and persistent pain on neck movement which subside for shorter duration with analgesic therapy4
4.  Occipital headacheScore
No headache0
Mild headache requiring no pain medication1
Moderate headache requiring nonprescription pain medication2
Severe headache requiring prescription pain3
5.  Restricted Neck Movement
FlexionScore
No restriction i.e., able to touch the interclavicular line0
Up to 2cm difference between the chin and interclavicular line1
2-4cm difference between the chin and interclavicular line2
More than 4cm difference3
ExtensionScore
Normal (i.e., able to extend the hand up to the level when tip of nose and forehead in horizontal plane approximately)0
Movement up to 120˚1
Movement up to 110˚ -120˚2
Movement less than 110˚3
Lateral flexionScore
Normal i.e., the ear touches the shoulder tip0
Up to 3cms difference between the ear and the shoulder tip1
5cms difference between the ear and the shoulder tip2
More than 5cms difference3
Lateral rotationScore
Normal i.e., able to make complete rotation of neck0
Rotation with little difficulty1
Rotation side to side only2
Rotation one side only3
6.  TinglingScore
Not at all0
A little bit (<25%)1
Somewhat (26-50%)2
Quite a bit (51-75%)3
Very much (>75%)4
7.  NumbnessScore
No symptoms0
Mild symptoms1
Moderate symptoms (limiting instrumental ADLS i.e., activities of daily living)2
Severe (limiting self-care ADLS)3

8.  DizzinessScore
Dizziness absent0
Mild unsteadiness or sensation of movement something1
Moderate unsteadiness or sensation of movement, limiting instrumental ADLS2
Severe unsteadiness or sensation of movement, limiting self-care ADLS3
9.  VertigoScore
Never0
A few times (1-3 times /year)1
Several times (4-12 times /year)2
Quite often (on average >1times /month)3
Very often (on average >1tinme /week)4
10. Grip weaknessScore
No contraction or muscle movements0
Trace of muscle contraction on attempt1
Active movement of muscle when gravity is eliminated2
Movements against gravity, but not against added resistance3
Movement against external resistance with less strength than usual4
Normal strength5

X-RAY Criteria:

1.  Intervertebral disk narrowingScore
None (0%)0
Mild (1-25%)1
Moderate (26-50%)2
Marked (51-75%)3
Severe (76-99%)4
Joint fusion (100%)5
2.  OsteophytesScore
None0
Small definite osteophytes(<2mm)1
Moderate osteophytes(2-4mm)2
Large (>4mm)3
3.  OlisthesisScore
None0
<3mm1
3-5mm2
>5mm3
4.  SclerosisScore
None0
Minimal1
Moderate2
Severe3

Observations and Results

90 patients were screened out of which 60 patients were selected on the basis of inclusion and exclusion criteria. Thus, total 60 patients were registered for the trial and randomly divided into two groups (30 patient in each group) out of which 29 patients were in Group A and 27 patients were in Group B completed the treatment respectively.


Demographic Data

Age: Maximum patient i.e., 47% were from the age group of 46- 60 years, followed by 28% were from age group of 20-35 years and rest 25% were of age group 36-45 years. This show that maximum sample population belongs to old age group as spondylotic changes increase with age.


In this age group Vata is more predominant, which takes pivot role for degenerative changes in tissue and can manifest as Asthigata Vata. But in recent scenario due to work profession and sedentary life style this disease also appears below this age group.

Gender: Cervical spondylosis usually starts earlier in men then in women.[5] Data reveals that both the sexes are equally affected by cervical spondylosis this difference in the study can even be neglected due to small sample size.

Religion: 75% of patient registered in study were Hindu 25 % were Muslim community. This may be due to the fact that Rishikul Campus is located in Haridwar, which is a Hindu predominant area.

Socio Economic Status: This data shows general trend of middle (38%) and lower middle (35%) class of patient to attend the OPD of Rishikul campus. But it can occur any of the class who are more exposed to neck strain or poor posture.

Nature of Work: The analysis of the data reveals that the majority of patients, i.e. 43% were field workers, followed by 36% desk job professional, 18% patients with long standing workers and 3% travelers. As we all know that cervical spondylosis is more common in patient with occupational stress, faulty sitting posture and continuous neck exertion.

Koshtha: Koshtha is the expression of bowel habits, which depends on Prakruti. In present study, 43% patients were Madhyama Koshtha, this shows that Kapha predominancy and Manda Agni, which is the most important culprit in the pathogenesis of cervical spondylosis while 30% were Kroora Koshtha and 27% were Mridu Koshtha.

Family History: It was found that maximum number of the patient 75% having negative family history. This show that as it is a degenerative disease so it has no relevance with family history.

Addiction: 64% addicted to tea/coffee, followed by smoking addiction in 14% patients & 10% patients consume tobacco. Excessive use of coffee & tobacco containing phosphorus, it prevents calcium absorption & thus leads to demineralization of bones.

Sleep: 57% enjoyed sound sleep, 43% patients had disturbed sleep, Pain in cervical spondylosis sometimes worsens at night thus may be resulting in disturbed sleep in these patients.[6]

Prakruti: The analysis of the gathered data reveals that the majority of patients, i.e., 38%, were Vata- Pittaja Prakriti, while 32% had Vata-Kaphaja Prakriti, and 30% had Pitta-Kaphaja Prakriti.

It suggests that Vata Kaphaja and Vata Pittaja Prakrti are more susceptible to degenerative disease as the property of increased Vata itself is destruction of bone and absorption of fluid that leads to Cervical Spondylosis.

Diet: The data from the current study indicates that the dietary choice among the patients were 55% mixed type of diet and 45% were vegetarian. Meat is a rich source of Sulphur which can change the pH of blood to acidic. Acidity of the blood leads to demineralization of bones.[7]

Vyayama Shakti: A maximum number of patients i.e., 43 (50%) were of Avara Vyayamashakti, 10 patients (16%) were of Pravara Vyayamashakti and 11.67% were of Madhyama Vyayamashakti Avara Vyayama Shakti indicates Avara Bala of patients in cervical spondylosis and another reason for Avara Vyayama Shakti may be due to the deformity caused by the disease factors that can make a person more likely to develop Spondylosis are being overweight and not exercising.

Chief Complaints

The analysis of the collected data reveals that pain and stiffness were present in almost 90% of the patient, 30% had occipital headache and 25-27% patient had dizziness.

As Pain and Stiffness are the main cardinal symptoms of Manyasthambha almost all the subjects were complaining about this along with a major number of subjects complaints about occipital headache and dizziness also. These symptoms occur when there is involvement of nerve root compression. Normally this nerve root compression is seen in later stages of cervical spondylosis.

Simple pain and stiffness will be neglected by most of the population until and unless it affects their day-to-day activities. And further deterioration of structures leads to degeneration of intervertebral discs and lead to these symptoms. In chronic and severe conditions of disease leads to severe nerve root compression and in such cases, occipital headache, dizziness and vertigo is observed on neck movements.


Observation of Clinical Study and Result
Subjective parameter

Table 1: Effect of Swedana and Agnikarma in Group-A on subjective parameters

Group ANMeanMedianSDWilcoxon WP-Value% EffectResult
BTATBTATBTAT
Pain (Vas scale)297.553.558.003.001.531.43-4.684b0.0000052.97HS
Stiffness261.280.591.001.000.650.50-4.264b0.0000254.05HS
Pain on neck movement271.410.901.001.000.680.49-3.441b0.0005836.59HS
Occipital Headache110.930.551.001.000.590.51-2.840b0.0045140.74VS
Restriction in Flexion80.280.140.000.000.450.35-2.000b0.0455050.00Sig
Restriction in Extension191.000.691.001.000.890.71-2.714b0.0066631.03VS
Restriction in lateral rotation220.860.591.001.000.580.50-2.309b0.0209232.00Sig
Restriction in lateral flexion180.620.521.001.000.490.51-1.732b0.0832616.67NS
Tingling261.311.031.001.000.710.57-2.309b0.0209221.05Sig
Numbness200.830.621.001.000.660.56-2.449b0.0143125.00Sig
Dizziness100.340.280.000.000.480.45-1.414b0.1573020.00NS
Vertigo90.340.280.000.000.550.53-1.414b0.1573020.00NS
Grip weakness0 (All are normal)000000000000000000NS

Table 2: Effect on X-ray findings

Group A (X -Ray)MeanMedianSDWilcoxon WP-Value% EffectResult
BTATBTATBTAT
Intervertebral disk narrowing0.210.210.000.000.410.41.000d1.000000.00NS
Osteophyte0.970.971.001.000.570.57.000d1.000000.00NS
Olisthesis0.070.070.000.000.260.26.000d1.000000.00NS
Sclerosis0.170.170.000.000.380.38.000d1.000000.00NS

Table 3: Effect of control drug in Group-B on subjective parameters

Group BNMeanMedianSDWilcoxon WP-Value% EffectResult
BTATBTATBTAT
Pain (Vas scale)277.593.418.003.001.500.84-4.573b0.0000055.12HS
Stiffness251.220.441.000.000.580.58-4.379b0.0000163.64HS
Pain on neck movement251.560.851.001.000.850.72-4.146b0.0000345.24HS
Occipital Headache81.070.631.001.000.550.49-3.207b0.0013441.38VS
Restriction in Flexion100.440.190.000.000.640.40-2.646b0.0081558.33VS
Restriction in Extension160.850.521.000.000.820.75-2.324b0.0201439.13Sig
Restriction in lateral rotation211.000.631.001.000.680.49-2.887b0.0038937.04VS
Restriction in lateral flexion190.740.521.001.000.530.51-2.121b0.0338930.00Sig
Tingling231.260.521.000.000.860.85-3.357b0.0007958.82HS
Numbness100.520.220.000.000.750.42-2.828b0.0046857.14VS
Dizziness60.220.150.000.000.420.36-1.414b0.1573033.33NS
Vertigo50.190.110.000.000.400.32-1.414b0.1573040.00NS
Grip weakness0
(All are normal)
000000000000000000NS

Table 4: Effect on X-ray findings

Group B (X-Ray)MeanMedianSDWilcoxon WP-Value% EffectResult
BTATBTATBTAT
Intervertebral disk narrowing0.300.300.000.000.540.54.000c1.000000.00NS
Osteophyte0.810.811.001.000.560.56.000c1.000000.00NS
Olisthesis0.110.110.000.000.320.32.000c1.000000.00NS
Sclerosis0.150.150.000.000.360.36.000c1.000000.00NS

(Table no.1) shows that trial therapy (Swedana and Agnikarma) provided a highly significant improvement (P< 0.001) in pain (52.97%), stiffness (54.05%) and pain in neck movement (36.56%), very significant was found in (P< 0.01) was found in occipital headache (40.74%) and restriction in extension (31.03) Significant (P<0.05) was found in restriction in flexion (50%), restriction in lateral rotation (32%), tingling (21.05%) and numbness (25%). And not significant (P≥0.05) was found in restriction in lateral flexion, dizziness, vertigo and grip weakness.

(Table no.2) shows p value for Intervertebral disk narrowing, Osteophyte, Olisthesis and Sclerosis is (P≥0.05) and the result was not significant for all parameters.

(Table no.3) shows that trial drug provides a Highly significant improvement (P<0.001) was found in pain (55.12), stiffness (63.64%), pain on neck movement (45.24%) and tingling (58.82%). Very significant improvement (P<0.01) was found in occipital headache (41.38%), restriction in flexion (58.33%), restriction in lateral rotation (37.04%), and numbness (57.14%), Significant improvement (P<0.05) was found in restriction in extension (39.13%) and restriction in lateral rotation (30.00% and not significant (P≥0.05) was found in dizziness, vertigo and grip weakness.

(Table no.4) shows p value for Intervertebral disk narrowing, Osteophyte, Olisthesis and Sclerosis is (P≥0.05) and the result was not significant for all parameters.

jaims_3959_02.JPG
Graph 1:
Percentage relief in subjective parameters in Group-A

jaims_3959_03.JPG
Graph 2:
Percentage relief in subjective parameters in Group-B

jaims_3959_04.JPG
Graph 3:
Inter Group Comparision of Subjective Parameter

Intergroup Comparison Result:

Inter group comparison not significant result (p ≥ 0.05) was found in all subjective parameter except tingling (as in tingling highly significant result was found). In both group X-Ray criteria shows non- significant result.

Comparative Assessment - However, in the term of percentage both groups has shown almost equal result but in tingling (58.82%), numbness (57.14%), dizziness (33.33%) & vertigo (40.00%) Group- B shows better result than Group- A


Table 5: Inter Group Comparison of Subjective Parameters

VariableGroupNMean RankSum of RanksMann-Whitney UP-ValueResult
Pain (Vas scale)Group A2927.78805.50370.5000.724NS
Group B2729.28790.50
Total56
StiffnessGroup A2627.33710.52357.5000.448NS
Group B2529.76743.98
Total51
Pain on neck movementGroup A2726.38712.24330.0000.250NS
Group B2530.78769.44
Total52
Occipital HeadacheGroup A1128.28311.08385.0000.904NS
Group B0828.74229.92
Total19
Restriction in FlexionGroup A826.86214.90344.0000.258NS
Group B1030.26302.59
Total18
Restriction in ExtensionGroup A1927.72526.76369.0000.669NS
Group B1629.33469.33
Total35
Restriction in lateral rotationGroup A2227.43603.48360.5000.560NS
Group B2129.65622.61
Total43
Restriction in lateral flexionGroup A1826.84483.21343.5000.254NS
Group B1930.28575.28
Total37
TinglingGroup A2623.09600.24234.5000.005HS
Group B2334.31789.24
Total49
NumbnessGroup A2027.29545.86356.5000.444NS
Group B1029.80297.96
Total30
DizzinessGroup A1028.43284.31389.5000.941NS
Group B628.57171.44
Total16
VertigoGroup A928.43255.88389.5000.941NS
Group B528.57142.87
Total14
Grip weaknessGroup A000000000NS
Group B00000
Total0 (All were having normal values)

Table 6: Post Treatment Effect on Follow-Up (Group A)

Group AMeanMedianSDWilcoxon WP-Value% ChangeResult
ATFUATFUATFU
Pain (Vas scale)3.554.103.003.001.432.47-1.634b>0.05-15.53NS
Stiffness0.590.901.001.000.500.67-2.324b<0.05-52.94Sig
Pain on neck movement0.900.791.001.000.490.56-1.342c>0.0511.54NS
Occipital Headache0.550.691.001.000.510.47-2.000b<0.05-25.00Sig
Restriction in Flexion0.140.170.000.000.350.38-1.000b>0.05-25.00NS
Restriction in Extension0.690.761.001.000.710.79-1.414b>0.05-10.00NS

Restriction in lateral rotation0.590.691.001.000.500.54-1.342b>0.05-17.65NS
Restriction in lateral flexion0.520.551.001.000.510.51-1.000b>0.05-6.67NS
Tingling1.031.171.001.000.570.66-1.633b>0.05-13.33NS
Numbness0.620.621.001.000.560.49.000d>0.050.00NS
Dizziness0.280.240.000.000.450.44-1.000c>0.0512.50NS
Vertigo0.280.280.000.000.530.53.000d>0.050.00NS
Grip weakness000000000000000000NS

Table 7: Post Treatment Effect on Follow-Up (Group B)

Group BMeanMedianSDWilcoxon WP-Value% ChangeResult
ATFUATFUATFU
Pain (Vas scale)3.416.743.008.000.842.41-3.742b<0.05-97.83Sig
Stiffness0.440.930.001.000.580.62-3.742b<0.05-108.33Sig
Pain on neck movement0.851.111.001.000.720.80-1.748b>0.05-30.43NS
Occipital Headache0.630.741.001.000.490.53-.905b>0.05-17.65NS
Restriction in Flexion0.190.370.000.000.400.56-1.414b>0.05-100.00NS
Restriction in Extension0.520.630.000.000.750.74-.577b>0.05-21.43NS
Restriction in lateral rotation0.630.631.001.000.490.56-.707b>0.050.00NS
Restriction in lateral flexion0.520.591.001.000.510.50-1.000b>0.05-14.29NS
Tingling0.520.480.000.000.850.58-.073c>0.057.14NS
Numbness0.220.330.000.000.420.55-1.732b>0.05-50.00NS
Dizziness0.150.190.000.000.360.40-1.000b>0.05-25.00NS
Vertigo0.110.190.000.000.320.40-1.000b>0.05-66.67NS
Grip weakness00000000000000000.00NS

Table 8: Inter Group Comparison of Subjective Parameters (At Vs Fu)

VariableGroupNMean RankSum of RanksMann-Whitney UP-ValueResult
Pain (Vas scale)Group A2933.83981.00237.000<0.05Sig
Group B2722.78615.00
Total56
StiffnessGroup A2630.14874.00344.000>0.05NS
Group B2526.74722.00
Total51
Pain on neck movementGroup A2732.81951.50266.500<0.05Sig
Group B2523.87644.50
Total52
Occipital HeadacheGroup A1128.41824.00389.000>0.05NS
Group B828.59772.00
Total19
Restriction in FlexionGroup A829.03842.00376.000>0.05NS
Group B1027.93754.00
Total18
Restriction in ExtensionGroup A1928.10815.00380.000>0.05NS
Group B1628.93781.00
Total35
Restriction in lateral rotationGroup A2227.26790.50355.500>0.05NS
Group B2129.83805.50
Total43
Restriction in lateral flexionGroup A1829.05842.50375.500>0.05NS
Group B1927.91753.50
Total37

TinglingGroup A2627.29791.50356.500>0.05NS
Group B2329.80804.50
Total49
NumbnessGroup A2029.90867.00351.000>0.05NS
Group B1027.00729.00
Total30
DizzinessGroup A1029.45854.00364.000>0.05NS
Group B627.48742.00
Total16
VertigoGroup A929.00841.00377.000>0.05NS
Group B527.96755.00
Total14
Grip weaknessGroup A000000000NS

Sig - Significant, NS - Non Significant

In Group A after completion of trial, statistically not significant (P>0.05) result was found in almost all subjective parameter except stiffness- (-52.94%) and occipital headache- (-25.00%) where the result was found significant. The percentage change in subjective parameter with non-significant result is- for pain (-15.53%), pain on neck movement- (11.54%), restriction in flexion- (-25.00%), extension- (-10.00%), lateral rotation- (-17.65%) and lateral flexion- (-6.67%), tingling- (-13.33%), numbness- (0.00%), dizziness- (12.50%) and vertigo- (0.00%).

It shows that there was long lasting effect found in all subjective parameters except (stiffness and occipital headache). In which there was significant relapse of symptoms.

In Group-B - Significant result (P<0.05) and change in percentage was found for pain (-97.83%) and stiffness (-108.33%) means there was relapse of symptoms whereas in pain on neck movement (-30.43%), occipital headache (-17.65%), restriction in flexion (-100.00%), extension (-21.43%), lateral rotation (0.00%), lateral flexion (-14.29%), tingling (7.14%), numbness (-50.00%), dizziness (-25.00%) and vertigo (-66.67%) the result was not significant (P≥0.05) which means there was long lasting effect.

On completion of follow up it has been observed that there is significant difference found between group A and group B on the pain (P<0.05). It was observed that group A has shown (-15.53%) while group B (-97.83%) result which indicate that there is lesser relapse in group A with comparison to group B.

For stiffness after completion of follow up not significant difference (P>0.05) was found in group A and group B. It was observed that group A has shown (-52.94%) while group B has shown (-108.33%) percentage changes in symptoms these findings indicates that there is lesser relapse in group A with comparison to group B. From above findings we can conclude that group B has seen severe relapse for stiffness. For pain in neck movement, it has been observed that there is significant difference found between group A and group B (P<0.05). It was observed that group A has shown (11.54%) while group B (-30.43%) percentage changes in symptom respectively, this data indicate that there is reoccurrence in group B while group A has shown much better response for pain in neck movement. For occipital headache, it has been observed that there is not significant result found in group A and group B (P>0.05) after completion of follow up. In the term of percentage change group A shows (-25%) changes in symptoms while group B has shown (-17.65%) which indicate that there is lesser relapse in group B with comparison to group A.

After completion of follow up there is not significant result (P>0.05) was found in group A and group B for parameters of restriction in flexion, extension, lateral rotation and lateral flexion but it has observed that group A has shown (-25%), (-10%), (-17.65%), and (-6.67%) changes in symptoms for above parameters respectively, while group B has shown (-100%), (-21.43%), (0.00), and (-14.29). So, we can conclude that group B shows severe relapse of symptoms after completion of follow up on maximum parameters while in group A effect of therapy was constant and long lasting.


On completion of follow up it has been observed that there is not significant (P>0.05) difference found between group A and group B for symptom tingling. It was observed that group A has shown (-13.33%) while group B (7.14%) percent relief in symptom which indicate that there is reoccurrence seen in group A while group B shows much better result for this parameter.

For numbness in group A symptom remains stable with (0.00%) changes in symptom while group B shows (-50%) which indicate severe revival.

On completion of follow up it has been observed that there is not significant (P>0.05) difference found between group A and group B for symptom dizziness. It was observed that group A has shown (12.50%) while group B (-25%) percent relief in symptom which indicate that there is reoccurrence seen in group B while group A shows much better result for this parameter.

On completion of follow up it has been observed that there is not significant (P>0.05) difference found between group A and group B for symptom vertigo. It was observed that group A has shown (0.00%) while in group B (-66.67%) percent relief in symptom which indicate that there is reoccurrence seen in group B while group A shows constant, better and long-lasting result for this parameter.

By above said findings we can state that after completion of trail both the group shown statistically insignificant result which means that both the group were equally effective, while in completion of follow up it can be clearly seen that result obtained in group A sustained for longer duration, whereas sever relapse is noted in group B.

With above observation we can say that both the groups show statistically significant relief in the sign and symptoms of cervical spondylosis (Manyastambha), after completion of treatment on inter group comparison insignificant difference was observed which means that both the group are equally effective in managing the disease.

While on comparison of follow up data, it has been seen that in group-A symptoms pain on neck movement (11.54%) and dizziness (12.50%), relief increased means relief keep on increasing after completion of treatment, some symptoms remain constant i.e. numbness and vertigo (0.00),

and in few symptoms like pain, restriction in flexion, extension, lateral rotation, lateral flexion, and tingling there is insignificant relapse is noted. In group B, significant relapse is observed in about all the symptoms. On inter group comparison, significant difference observed on completion of follow up which, indicate group A is better than group B.

Table 9: Assessment of Overall Response of Treatment

Overall EffectGroup AGroup B
N%N%
Marked Improvement26.90%00.00%
Moderate Improvement724.14%1659.25%
Mild Improvement1655.17%933.33%
No Improvement413.79%27.40%
Total29100.00%27100%

Discussion

The purpose of this clinical study is to give cervical spondylosis patient which is a common yet impactful disorder a better diagnosis and course of treatment. The term “cervical spondylosis” refers to a broad spectrum of progressive degenerative alterations that affect every component of the cervical spine.

(i.e., intervertebral discs, facet joints, joints of Luschka, ligamentum flava, and laminae). Cervical spondylosis symptoms include neck pain, neck stiffness and it may be followed by radicular symptoms, when neural structures are compressed.

After low back pain, neck pain is a second most common widespread complaint. It is Imperative for health care practitioners to identify cervical spondylosis symptoms and offer cost effective intervention, evidence-based solutions. Manyastambha has been enumerated in Vata Nanatmaja Vikara where the vitiated Vata get lodged into Manyasamshrita Nadi resulting in Sthamba and Shoola in Manya Pradesh. Degenerative diseases can be included under the heading of Vata Vyadhi.

According to Acharya Sushruta Manyastambha is Vata- Kaphaja Vyadhi in acute stage where Stambha and Gauravta are present, at this point Kapha is predominant vitiated Dosha so firstly Avarana is removed by Ruksha Baluka Swedana due to its Agnideepana property.


Vata performs a secondary role in the disease’s etiopathogenesis after going over the Punnagadi Potali which is explained in Vata Vyadhi Adhikara in Yogaratankar is chosen for pacifying vitiated Vata Dosa it is an unparalleled treatment in painful conditions caused mainly by Vata Dosha, usually in degenerative diseases. Agnikarma having anti Vata Kapha properties like Ushana, Sukshma, Ashukarigunamaya so helpful in relieving pain and muscle spasm instantly. And also aims for the achievement of Apunarbhava Chikitsa. So Agnikarma is chosen in the last step of the procedure as Harita stated in Chikitsa Sthana that Yantra, Kshar, and Ausadha, acts as Pathya means acts better when given after Swedana and Mardana.

Conclusion

The clinical presentation of Manyastambha closely resemblance with the sign and symptoms of cervical spondylosis it clearly states the pathogenesis of the neck and its contents. The treatment procedure described in Ayurveda focuses not only on drugs but also lifestyle modification. In this research study the above statistical data proves that after completion of trail both the group shown statistically insignificant result which means both the groups were equally effective. But on follow group A (Swedana and Agnikarma) sustained for longer duration, whereas sever relapse is noted in group B (Controlled drug). It should be recommended that the study should be repeated by taking large sample size with longer duration to see more accurate results and the recurrence of disease in follow ups.

References

1. Allagappan R. Manual of Practical Medicine. 6th ed. Jaypee Brothers Medical (P) Ltd. ; 2018. p. 720 [Crossref][PubMed][Google Scholar]

2. Agnivesha. Charaka Samhita. In: Sastri K, Chaturvedi G, editors. Vidyotini Hindi commentary. Reprint ed. Delhi: Chaukhambha Sanskrit Pratishthan; 2015. Sutra Sthana, 20/11. p. 399 [Crossref][PubMed][Google Scholar]

3. Shastri AD. Sushrut Samhita. Purvardh Nidan Sthan 1/67. In: Shastri AD, editor. Ayurved Tattav Sandipika Hindi commentary. Varanasi: Chaukhambha Orientalia; Part 1. p. 303 [Crossref][PubMed][Google Scholar]

4. Agnivesha. Charaka Samhita. In: Sastri K, Chaturvedi G, editors. Vidyotini Hindi commentary. Reprint ed. Delhi: Chaukhambha Sanskrit Pratishthan; 2015. Sutra Sthana, 14/25-26. p. 286 [Crossref][PubMed][Google Scholar]

5. Overview. Available from: https://emedicine. medscape. com/article/306036-overview#a6. Accessed 2019 Apr 25 [Crossref][PubMed][Google Scholar]

6. Scientific reports. Available from: https://www. omicsonline. org/scientific-reports/srep193. php.Accessed 2019 Apr 25 [Crossref][PubMed][Google Scholar]

7. Scientific reports. Available from: https://www. omicsonline. org/scientific-reports/srep193. php.Accessed 2019 Apr 25 [Crossref][PubMed][Google Scholar]

Disclaimer / Publisher's NoteThe statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Journals and/or the editor(s). Journals and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.